NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Nicardipine Hydrochloride In 0.83% Sodium Chloride, and when can generic versions of Nicardipine Hydrochloride In 0.83% Sodium Chloride launch?
Nicardipine Hydrochloride In 0.83% Sodium Chloride is a drug marketed by Inforlife and is included in one NDA.
The generic ingredient in NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE is nicardipine hydrochloride. There are eleven drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the nicardipine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nicardipine Hydrochloride In 0.83% Sodium Chloride
A generic version of NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE was approved as nicardipine hydrochloride by ANI PHARMS on October 28th, 1996.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE?
- What are the global sales for NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE?
- What is Average Wholesale Price for NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE?
Summary for NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Clinical Trials: | 53 |
Formulation / Manufacturing: | see details |
DailyMed Link: | NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE at DailyMed |
![NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE drug patent expirations Drug patent expirations by year for NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE](/p/graph/s/t/NICARDIPINE_HYDROCHLORIDE_IN_0.83%_SODIUM_CHLORIDE-patent-expirations.png)
Recent Clinical Trials for NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Boston Medical Center | Phase 4 |
University of Illinois at Chicago | Early Phase 1 |
Nanjing First Hospital, Nanjing Medical University | N/A |
See all NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE clinical trials
US Patents and Regulatory Information for NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Inforlife | NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE | nicardipine hydrochloride | INJECTABLE;INTRAVENOUS | 203978-002 | Apr 17, 2024 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |